The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts.

The link you have selected will take you outside of Albireo Pharma’s corporate website. The site you will be entering is intended for U.S. audiences only. Go Back. Continue. YOU ARE NOW LEAVING ALBIREOPHARMA.COM. You are now leaving Albireo Pharma’s corporate website. Albireo does not control or endorse the content of this external site.

Now accepting applications for SPARK™ - Albireo’s Grants in Rare Liver Disease program. Learn more.

– Evidence of long-term clinical treatment benefit of Bylvay™ (odevixibat) showing improved liver health and function across PFIC types – – Data show Bylvay therapy up to 128 weeks, sustained improvements in hepatic health, quality of sleep and growth, reducing disease burden – – First data on A2342, the first oral systemic NTCP inhibitor, shows inhibition of Hepatitis B viral ...

prescription drugs available in the same therapeutic class as Albireo Pharma Inc. s products based on the products labeled indication s. The prices listed below are WAC prices as published by )LUVW'DWDEDQN ,QF. WAC prices are representative of the price paid by wholesalers but the actual price paid by consumers may differ significantly from the ...

Now accepting applications for SPARK™ - Albireo’s Grants in Rare Liver Disease program. Learn more.

FortiGate